Outputs

Latest published work and other ISARIC outputs

You can use the tools below to filter documents and other materials by category. If you have questions about access to documents or citing our research, please contact us.

An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus an aminoglycoside + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial-an update to the published protoco

Learn more

Experiences and challenges with the new European Clinical Trials Regulation

Learn more

Community Involvement in an Outbreak—One Year on for Mpox

Learn more

MOSAIC Clade 2b Mpox cohort study: Clinical Characterisation and Outcomes

Learn more

Nipah Virus Therapeutics: A Systematic Review to Support Prioritisation for Clinical Trials (Preprint)

Learn more

Developing a value proposition for sustainable R&D and availability of Lassa fever therapeutics in West Africa

Learn more

Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing

Learn more

Adeno-associated virus 2 infection in children with non-A–E hepatitis

Learn more

Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Learn more

Global challenges in preparedness and response to epidemic infectious diseases

Learn more

Waking up to monkeypox

Learn more

Breakthrough treatments for Ebola virus disease, but no access—what went wrong, and how can we do better?

Learn more

From private incentives to public health need: rethinking research and development for pandemic preparedness

Learn more

An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus streptomycin + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial

Learn more

Expanded Access Protocol for the use of tecovirimat for the treatment of monkeypox infection: a study protocol for an Expanded Access Programme

Learn more

Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study

Adults and children can develop post-Covid-19 condition (PCC) (also referred to as Long Covid). However, existing evidence is scarce, partly due to a lack of a standardised case definition, short follow up duration, and heterogenous study designs, resulting in wide variation of reported outcomes. The primary aim of this study was to characterise risk factors for PCC and longitudinal rates of recovery in a cohort of children and young people using a standardised protocol. Learn more

Laboratory diagnosis of mpox in the Central African Republic 2016-2022

Learn more

A cohort study of Post COVID-19 Condition across the Beta, Delta and Omicron waves in South Africa: 6-month follow up of hospitalised and non-hospitalised participants

Learn more

Extended coagulation profile of children with Long Covid: a prospective study

Learn more

Preparing for pandemics: a systematic review of pandemic influenza clinical management guidelines

Learn more

An evaluation of global Chikungunya clinical management guidelines: A systematic review.

Learn more

What is the standard of care for Viral Haemorrhagic Fevers (VHFs)?: a systematic review of clinical management guidelines for high priority VHFs

Learn more

Implementation of clinical management guidelines for infectious diseases: a systematic review

Learn more

Characteristics Of Care Programs For Pediatric Post-COVID Condition

Learn more

Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study

Learn more

Post-COVID Condition in Adults and Children Living in the Same Household in Italy: A Prospective Cohort Study Using the ISARIC Global Follow-Up Protocol.

Learn more

Post-COVID-19 condition in children: a COS is urgently needed

Learn more

Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID)

Learn more

Availability, scope and quality of monkeypox clinical management guidelines globally: a systematic review

Learn more

Severe acute hepatitis of unknown aetiology in children – what is known?

Learn more

Lack of Evidence for Ribavirin Treatment of Lassa Fever in Systematic Review of Published and Unpublished Studies

Learn more

Post COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study’.

Learn more

An evaluation of global Chikungunya clinical management guidelines – a systematic review

Learn more

A standardised Phase III clinical trial framework to assess therapeutic interventions for Lassa fever

Learn more

Risk factors for long-term consequences of COVID-19 in hospitalised adults in Moscow using the ISARIC Global follow-up protocol: StopCOVID cohort study

Learn more

Defining what matters for the treatment of Measuring Post-COVID-19 condition: the critical importance of Core Outcome Set development

Learn more

Comparative evaluation of ten lateral flow immunoassays to detect SARS -CoV-2 antibodies

Learn more

Tecovirimat for Monkeypox in Central African Republic under Expanded Access

Learn more

Final Report – Analysis of a Clinical Trial: Ribavirin and The Treatment Of Lassa Fever

This is a copy of the Report Analysis of a Clinical Trial for Ribavirin and the Treatment of Lassa Fever. The data were collected by the US Centers for Disease Control under their IND 17186. Learn more

Addressing stigma in infectious disease outbreaks: a crucial step in pandemic preparedness

Learn more

Ethnicity and Outcomes from COVID-19: The ISARIC CCP-UK Prospective Observational Cohort Study of Hospitalised Patients

Learn more

Rolling out COVID-19 antigen rapid diagnostic tests: the time is now

Learn more

Scaling up COVID-19 rapid antigen tests: promises and challenges

Learn more

Time to reconsider the role of ribavirin in Lassa fever

Learn more

Managing the risks of making the wrong diagnosis: First, do no harm

Learn more

Lightweight Transformers for Clinical Natural Language

Learn more

Systematic Review of Scales for Measuring Infectious Disease-Related Stigma

Infectious disease outbreaks are associated with substantial stigma, which can have negative effects on affected persons and communities and on outbreak control. Thus, measuring stigma in a standardized and validated manner early in an outbreak is critical to disease control. We reviewed existing scales used to assess stigma during outbreaks. Our findings show that many different scales have been developed, but few have been used more than once, have been adequately validated, or have been ... Learn more

Modeling the relative influence of socio-demographic variables on post-acute COVID-19 quality of life: an application to settings in Europe, Asia, Africa & South America – Preprint

Learn more

Plasma steroid concentrations reflect acute disease severity and normalise during recovery in people hospitalised with COVID-19

Endocrine systems are disrupted in acute illness, and symptoms reported following coronavirus disease 2019 (COVID-19) are similar to those found with clinical hormone deficiencies. We hypothesised that people with severe acute COVID-19 and with post-COVID symptoms have glucocorticoid and sex hormone deficiencies. Learn more

Involve those, who are managing these outbreaks’ – Identifying barriers and facilitators to the implementation of clinical management guidelines for High-Consequence Infectious Diseases in Uganda – Preprint

Learn more

Long-term neurological symptoms after acute COVID-19 illness requiring hospitalization in adult patients: insights from the ISARIC-COVID-19 follow-up study

Learn more

Variability in clinical assessment of clade IIb mpox lesions

Learn more

Evaluation of pragmatic oxygenation measurement as a proxy for COVID-19 severity

Learn more

Mpox: the alarm went off. Have we gone back to sleep?

Learn more

MOSAIC: A cohort study of human mpox virus disease [version 2; peer review: 1 approved]

Learn more

Use of an extended KDIGO definition to diagnose acute kidney injury in patients with COVID-19: A multinational study using the ISARIC–WHO clinical characterisation protocol

Learn more

Neurological manifestation and outcome for patients admitted to hospital with COVID-19: Results from the ISARIC prospective multinational observational study

Learn more

Characteristics and outcomes of an international cohort of 400,000 hospitalised patients with Covid-19

Learn more

International comparison of age-specific presenting symptoms for patients admitted to hospital with coronavirus disease 2019

Learn more

Co-infections and antimicrobial usage in hospitalised patients with COVID-19 from the ISARIC WHO CCP-UK study: a prospective, multicentre cohort study

Learn more

Accessibility and implementation of COVID-19 clinical management guidelines produced early in the COVID-19 pandemic: a global survey.

Learn more

Evidence of lung perfusion defects and ongoing inflammation in an adolescent with Post-Acute sequelae SARS-CoV-2 infection

Learn more

What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? – a harmonised, global longitudinal observational study protocol

Learn more

COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospectve multinational observational study

The ISARIC prospective multinational observational study is the largest cohort of hospitalized patients with COVID-19. We present relationships of age, sex, and nationality to presenting symptoms. Learn more

Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development

Learn more

The impact of COVID-19 on clinical research for Neglected Tropical Diseases (NTDs): a case study of bubonic plague

Among the many collaterals of the COVID-19 pandemic is the disruption of health services and vital clinical research. COVID-19 has magnified the challenges faced in research and threatens to slow research for urgently needed therapeutics for Neglected Tropical Diseases (NTDs) and diseases affecting the most vulnerable populations. Here we explore the impact of the pandemic on a clinical trial for plague therapeutics and strategies that have been considered to ensure research efforts continue. Learn more

Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19: An observational cohort

Learn more

The value of open-source clinical science in pandemic response: lessons from ISARIC

Learn more

Clinical characterization of Lassa fever: a systematic review of clinical reports and research to inform clinical trial design

Research is urgently needed to reduce the morbidity and mortality of Lassa fever (LF), including clinical trials to test new therapies and to verify the efficacy and safety of the only current treatment recommendation, ribavirin, which has a weak clinical evidence base. To help establish a basis for the development of an adaptable, standardised clinical trial methodology, we conducted a systematic review to identify the clinical characteristics and outcomes of LF and describe how LF has ... Learn more

Setting priorities to address research gaps in Long-term COVID-19 outcomes in children

Learn more

Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: A prospective, multicentre cohort study

COVID-19 is a multisystem disease and patients who survive might have in-hospital complications. These complications are likely to have important short-term and long-term consequences for patients, health-care utilisation, health-care system preparedness, and society amidst the ongoing COVID-19 pandemic. Our aim was to characterise the extent and effect of COVID-19 complications, particularly in those who survive, using the International Severe Acute Respiratory and Emerging Infections ... Learn more

Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19

The long-term sequalae of COVID-19 remain poorly characterized. We assessed persistent symptoms in previously hospitalized patients with COVID-19 and assessed potential risk factors. Learn more

Risk factors for long-term consequences of COVID-19 in hospitalised children in Moscow using the ISARIC Global follow-up protocol: StopCOVID cohort study – Preprint

Learn more

Evaluating clinical characteristics studies produced early in the Covid-19 pandemic:a systematic review

Clinical characterisation studies have been essential in helping inform research, diagnosis and clinical management efforts, particularly early in a pandemic. This systematic review summarises the early literature on clinical characteristics of patients admitted to hospital, and evaluates the quality of evidence produced during the initial stages of the pandemic. Learn more

Characterising long-term covid-19: a living systematic review

Learn more

Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK

Learn more

What are the long-term symptoms and complications of COVID-19: a protocol for a living systematic review

Learn more

Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): a prospective cohort study

Learn more

Bubonic plague: can the size of buboes be accurately and consistently measured with a digital calliper?

Learn more

A systematic review of the clinical profile of patients with bubonic plague and the outcome measures used in research settings

Learn more

Monkeypox: how will we know if the treatments work?

Learn more

Research priorities for Long Covid: refined through an international multi-stakeholder forum

Learn more

Nipah virus disease: what can we do to improve patient care?

We propose a regionally led, patient-centred, and public health-centred, end-to-end framework that articulates a public health vision and a roadmap for research, development, manufacturing, and access towards the goal of improving patient outcomes. This framework includes co-creating a regulatory-compliant, clinically meaningful, and context-specific clinical development plan and establishing quality standards in clinical care and research capabilities at sites where the disease occurs. The Learn more

Clinical REsearch During Outbreaks (CREDO) Training for Low- and Middle-Income Countries

Learn more